bioAffinity Technologies

bioAffinity Technologies Addressing the need for noninvasive diagnosis of early-stage cancer and targeted cancer treatment. www.cypathlung.com

Our flagship product, CyPath® Lung, is a noninvasive early lung cancer diagnostic.

Join a multidisciplinary panel of physicians for an insightful discussion on CyPath® Lung’s expanding role in pulmonary,...
06/05/2026

Join a multidisciplinary panel of physicians for an insightful discussion on CyPath® Lung’s expanding role in pulmonary, oncology and surgical practices for the detection and management of early-stage lung cancer.

📅 June 16, 2026 at 7 p.m. ET

🎓 Hosted by the Society for Advanced Bronchoscopy (SAB)

Register at https://bit.ly/3PaFPSR

06/05/2026

CyPath® Lung provides early, real-time insight into pulmonary nodules, helping care teams decide when intervention is needed or when continued CT imaging is more appropriate.

The test supports confident, data-driven decisions and efficient care planning. The results provide timely identification of whether a nodule is "Likely" or "Unlikely" malignancy that allow clinicians and their patients to act with greater confidence.

Learn how: https://cypathlung.com/

06/03/2026

Actionable results can change the course of care.

CyPath® Lung identifies whether a pulmonary nodule is “Likely” malignancy in the lung or “Unlikely” malignant, helping clinicians determine the most appropriate next steps. Early insight allows for timely intervention when needed, or supports watchful waiting with continued CT imaging when a result is "Unlikely.”

Learn more: https://www.cypathlung.com/

Mark your calendars! 📅 SAB hosts live webinar featuring CyPath Lung on June 16 at 7 p.m. ET. ⬇️A dynamic multidisciplina...
06/02/2026

Mark your calendars! 📅 SAB hosts live webinar featuring CyPath Lung on June 16 at 7 p.m. ET. ⬇️

A dynamic multidisciplinary panel will include an interventional pulmonologist, a medical oncologist, and a thoracic surgeon who will tell you how they are integrating CyPath® Lung into their practices for the early detection and management of lung cancer.

Join the Society for Advanced Bronchoscopy for “Navigating Lower Cancer-Risk Nodules in High-Risk Patients with Noninvasive CyPath® Lung Testing.”

Learn how flow cytometry + AI with at-home sample collection can provide additional clinical insight and improve patient outcomes.

It’s an honor to collaborate with the SAB to provide meaningful insight on innovative tools like the noninvasive CyPath® Lung test that support earlier diagnosis, better risk stratification and more-informed decision-making for treatment and follow-up.

If you are a clinician, pulmonologist, oncologist, thoracic surgeon, healthcare professional, or anyone interested in learning more, we invite you to register for the free webinar.

Read the press release: https://bwnews.pr/4ufoZ3B or register directly here: https://bit.ly/4dLTCZy

05/29/2026

Not all pulmonary nodules require intervention, but distinguishing low-risk nodules is essential for effective management.

CyPath® Lung delivers actionable diagnostic information that helps clinicians identify nodules unlikely to be malignant, guiding watchful waiting strategies and ensuring resources are used where they’re most needed. This added clarity supports more confident, informed care decisions.

Learn more: https://www.cypathlung.com/

05/28/2026

In pulmonary care, timing can impact outcomes.

CyPath® Lung delivers actionable results within 3 days after a sample reaches the laboratory, giving clinicians the information they need to guide next steps with confidence. This insight supports informed care planning and reassurance for patients navigating indeterminate nodules.

Learn more: https://www.cypathlung.com/

bioAffinity Technologies continues to expand our global protection for the groundbreaking technology behind our noninvas...
05/27/2026

bioAffinity Technologies continues to expand our global protection for the groundbreaking technology behind our noninvasive CyPath Lung test for lung cancer. Mexico's patent office has notified us of a new patent protecting our use of flow cytometry to analyze sputum for the early detection of lung cancer. A strong IP portfolio creates value for shareholders. Our proprietary technology supports clinicians in evaluating indeterminate pulmonary nodules and risk stratifying high-risk patients.

Advanced cell biology + flow cytometry + AI differentiates CyPath Lung. We thank the Mexican Institute of Industrial Property for recognizing the value of our work with this new patent. https://bwnews.pr/4tVsn3v

Only about 1 in 4 eligible Americans were up to date with lung cancer screening in 2024, according to a research letter ...
05/22/2026

Only about 1 in 4 eligible Americans were up to date with lung cancer screening in 2024, according to a research letter posted on JAMA at https://bit.ly/42SLGiN

The study also found disparities in screening uptake by age, race/ethnicity and insurance status, underscoring the need for greater access, awareness and tools that support earlier detection.

Early detection matters. CyPath Lung can make a difference

05/22/2026

CyPath® Lung enhances diagnostic understanding, providing actionable results that help clinicians guide patients confidently.

Early insight supports better outcomes and reassurance for patients navigating uncertainty. When making timely decisions about pulmonary nodules becomes challenging, CyPath® Lung can provide clarity on whether watchful waiting or intervention is called for.

Learn how: https://cypathlung.com

bioAffinity Technologies appreciates the opportunity to collaborate with the American Lung Association to advance lung h...
05/20/2026

bioAffinity Technologies appreciates the opportunity to collaborate with the American Lung Association to advance lung health initiatives. As a member of the ALA Health Industry Council, we are able to support ALA's mission through industry input, sponsorship and program participation.

Address

3300 Nacogdoches Road Ste 216
San Antonio, TX
78217

Telephone

+12106985334

Website

Alerts

Be the first to know and let us send you an email when bioAffinity Technologies posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category